Prognostic role of p53 in stage III non-small cell lung cancer

被引:0
作者
Berghmans, T
Mascaux, C
Martin, B
Ninane, V
Sculier, JP
机构
[1] Inst Jules Bordet, Dept Crit Care & Thorac Oncol, B-1000 Brussels, Belgium
[2] Hop St Pierre & Erasme, Dept Pneumol, B-1000 Brussels, Belgium
关键词
p53; non-small cell lung cancer; staging; prognostic factors;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: New biological factors have not been extensively studied in stage III non-small cell lung cancer (NSCLC). Ire aimed to determine the role of p53 as a prognostic factor in such patients. Materials and Methods: p53 expression was assessed by immunohistochemisny and evaluated by three independent observers. The Cox model was used to assess the impact of clinical and biological factors on patient survival. Results: Between 01/1987 and 07/2002, 93 stage 111 NSCLC patients were included. Twenty-eight had a p53 positive tumour. There was no survival difference among patients with p53-positive and -negative tumours (p=0.46). In multivariate analysis, 3 factors were statistically significantly associated with survival: surgical resection (p=0.009), good performance status (p=0.02) and low creatinine level (p=0.02). Conclusion: Good performance status, surgical resection and low creatinine level were independent favourable prognostic factors for survival in stage III NSCLC while p53 was not, even in univariate analysis.
引用
收藏
页码:2385 / 2389
页数:5
相关论文
共 26 条
[11]   MOLECULAR AND BIOLOGICAL FACTORS IN THE PROGNOSIS OF NON-SMALL-CELL LUNG-CANCER [J].
KANTERS, SDJM ;
LAMMERS, JWJ ;
VOEST, EE .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (08) :1389-1397
[12]   Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy [J].
Langendijk, H ;
Thunnissen, E ;
Arends, JW ;
de Jong, S ;
ten Velde, G ;
Lamers, R ;
Guinee, D ;
Holden, J ;
Wouters, M .
RADIOTHERAPY AND ONCOLOGY, 2000, 56 (02) :197-207
[13]   The 1997 International Staging System for non-small cell lung cancer - Have all the issues been addressed? [J].
Leong, SS ;
Lima, CMR ;
Sherman, CA ;
Green, MR .
CHEST, 1999, 115 (01) :242-248
[14]  
Martin B, 2002, ONCOL REP, V9, P223
[15]   Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 [J].
Mascaux, C ;
Martin, B ;
Verdebout, JM ;
Meert, AP ;
Ninane, V ;
Sculier, JP .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :753-758
[16]   Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer [J].
Meert, AP ;
Martin, B ;
Verdebout, JM ;
Paesmans, M ;
Berghmans, T ;
Ninane, V ;
Sculier, JP .
LUNG CANCER, 2004, 44 (03) :295-301
[17]  
Mitsudomi T, 1995, ANN ONCOL, V6, P9
[18]   Revisions in the International System for Staging Lung Cancer [J].
Mountain, CF .
CHEST, 1997, 111 (06) :1710-1717
[19]   Immunocytochemical markers in stage I lung cancer: Relevance to prognosis [J].
Pastorino, U ;
Andreola, S ;
Tagliabue, E ;
Pezzella, F ;
Incarbone, M ;
Sozzi, G ;
Buyse, M ;
Menard, S ;
Pierotti, M ;
Rilke, F .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2858-2865
[20]  
RUSCH V, 1995, CANCER RES, V55, P5038